Slide 1: Result presentation Q3/2020
25 November 2020, Seppo Kopsala, CEO / Lars Lindqvist, CFO Result presentation Q3/2020
Slide 2: Highlights
Highlights OPT@MED
Slide 3: Highlights
Deliveries to the major Devices segment’s revenue 1. Chinese customer continued 4. picking up from Q2 Gross Profit, Gross Margin and Long term prospects remain 2. 5. unchanged in spite of the Highlights EBITDA all increased pandemic Successful quarter for the The outlook 2020 3. Software segment due
Slide 4: Focus areas
Focus areas China: • Deliveries to our major Chinese customer continued • Sales of EY80 for new-born eye screenings have started • Optomed Aurora CFDA approval received after the review period USA: • The US expansion progressing as planned, first sales to key customers • FDA study with AEYE Health s
Slide 5: COVID-19 Coronavirus
COVID-19 Coronavirus • COVID-19 Coronavirus pandemic continues • What does it mean to Optomed: • Devices segment sales continue to be affected as the market standard sales model is face-to-face: adjusting to virtual sales efforts • OEM customers continue to decrease their inventories by postponing o
Slide 6: Q3/2020 Financial highlights (KEUR)
Q3/2020 Financial highlights (KEUR) Q3/2020 Q3/2019 Change Revenue 3,338 3,551 -6.0% Gross profit 1) 2,262 2,035 11.2% Gross margin 2) 67.8% 57.3% 10.5 bps Adjusted EBITDA 229 -160 243.1% Adjusted EBITDA margin 6.9% -4.5% +11.4 bps Net profit/ loss -299 -1,256 76.2% Earnings per share -0.02 -0.14 83
Slide 7: 1-9/2020 Financial highlights (KEUR)
1-9/2020 Financial highlights (KEUR) 1-9/2020 1-9/2019 Change Revenue 8,969 10,649 -15.8% Gross profit 1) 6,146 7,199 -14.6% Gross margin 2) 68.5% 67.6% 0.9 bps Adjusted EBITDA -671 19 -3565.4% Adjusted EBITDA margin -7.5% 0.2% -7.7 bps Net profit/ loss -2,525 -2,817 10.4% Earnings per share -0.19 -
Slide 8: Devices segment highlights
Devices segment highlights
Slide 9: Devices segment highlights
7-9/2020 7-9/2019 Change Revenue increased from Q2 1. despite the market is still affected Devices segment highlights by the pandemic Revenue 1,537 1,863 -17.5% Deliveries to a major Chinese 2. customer continued Gross profit 933 768 21.4% Gross margin 60.7% 41.2% 19.5 bps EBITDA improved due to cos
Slide 10: Software segment highlights
Software segment highlights
Slide 11: Software segment highlights
7-9/2020 7-9/2019 Change Successful quarter due to 1. the recurring revenue model Software segment highlights Revenue 1,802 1,688 6.7% The travel restriction due to the 2. pandemic have slowed down the Gross profit 1,330 1,267 5.0% global screening solution sales Gross margin 73.8% 75.0% -1.2 bps EB
Slide 12: Outlook 2020
Outlook 2020
Slide 13: Outlook 2020
Outlook 2020 We continue to progress our expansion towards the US market and grow our international distributor network. Additionally, we are currently investing in the development of our first fully integrated AI camera with expected commercial launch during 2020. Optomed expects its revenue to dec
Slide 14: Financial targets
Financial targets Revenue Growth Adjusted EBITDA Optomed’s medium-term target is to deliver Optomed’s target is to prioritise a double-digit annual organic revenue investments in the organisation to growth. In the long-term Optomed’s target support growth in the medium-term and is to deliver an aver
Slide 15: Balance sheet
Balance sheet 30.9.2020 30.9.2019 Balance sheet ASSETS Goodwill 4,256 4,256 Development costs 5,386 5,257 • Equity ratio of 66.5 (28.0) percent Other intangible assets 2,910 3,168 Total intangible assets 12,552 12,681 • Total borrowings of EUR 6.5 (10.1) Total tangible assets 1,129 1,310 million. EU
Slide 16: Cash flow
Q3 2020 Q3 2019 Cash flow Loss for the financial year -299 -1,256 Cash flows before change 306 -488 • Cash flow from operating activities in net working capital amounted to EUR -0.4 (-0.5) million Change in net working capital -692 76 Cash flows before finance items -386 -412 • Strong cash position
Slide 17: Optomed's mission is to prevent blindness by improving access to eye screening
“ Optomed’s mission Expansion into new geographical markets is to prevent blindness by improving access to eye screening globally Opening new customer segments: primary care Bringing AI-integrated health screening to the market
Slide 18: Appendix
Appendix OPT@MED
Slide 19: Devices Segment 1-9/2020 financials
Devices Segment 1-9/2020 financials 1-9/2020 1-9/2019 Change % Revenue 3,359 5,152 -34.8% Gross profit 1,872 3,087 -39.4% Gross margin 55.7% 59.9% -4.2 bps EBITDA -251 -240 -4.8% EBITDA margin -7.5% -4.7% -2.8 bps
Slide 20: Software Segment 1-9/2020 financials
Software Segment 1-9/2020 financials 1-9/2020 1-9/2019 Change % Revenue 5,610 5,497 2.1% Gross profit 4,274 4,112 3.9% Gross margin 76.2% 74.8% 1.4 bps EBITDA 1,291 1,190 8.4% EBITDA margin 23.0% 21.7% 1.3 bps
Slide 21: Cash flow 1-9/2020
Cash flow 1-9/2020 1-9/2020 1-9/2019 Loss for the financial year -2525 -2,817 Cash flows before change in net working capital -457 -545 Change in net working capital -2,512 -1,035 Cash flows before finance items -2,969 -1,580 Cash flows from finance items -246 -259 Net cash from operating activities
Slide 22: Optomed Plc. contact details
Optomed Plc. Yrttipellontie 1, 90230 Oulu, Finland Tel: +358 20 741 3380 • investors@optomed.com www.optomed.com